OXFD | IJB95/96 | JNIadj | JNImeta | |
---|---|---|---|---|
(n = 77) | (n = 212) | (n = 139) | (n = 270) | |
Mean age at diagnosis | ||||
(years) | 64 | 58.5 | 64 | 58 |
(range) | (40-86) | (31-87) | (46-87) | (26-89) |
Menopausal status | ||||
Premenopausal | / | 54 | 7 | 95 |
Postmenopausal | / | 135 | 132 | 175 |
UK* | 77 | 23 | 0 | 0 |
Event free survival | DMFS/ | DMFS/ | RFS/ | Progression/ |
(mean; months) | 67 | 78.7 | 46 | 13.4 |
(range) | (0.26-129) | (0.13-142.27) | (2-129) | (1-70) |
Death | ||||
Yes | / | 24 | 51 | 179 |
No | / | 188 | 88 | 91 |
Tumor size | ||||
≤2 | 31 | 95 | 25 | / |
>2 | 46 | 95 | 81 | |
(mean) | 3.14 | 2.29 | 2.6 | |
(range) | (1-7) | (0.15-8) | (1-8) | |
UK* | 22 | 33 | ||
Histological grade | ||||
1 | 13 (16.7%) | 37 (17.5%) | 1 (0.01%) | 1 (0.003%) |
2 | 40 (51.2%) | 89 (42.5%) | 16 (11.5%) | 34 (12.6%) |
3 | 13 (16.7%) | 83 (39.2%) | 77 (55.4%) | 154 (57.0%) |
UK* | 11 (15.4%) | 3 (0.01%) | 45 (32.3%) | 81 (30.0%) |
Number of metastasis sites | ||||
0 | 50 | 171 | / | / |
1 | 24 | 20 | ||
2 | 3 | 19 | ||
≥ 3 | 0 | 2 | ||
Histo. Estrogen Receptor status (>10% or ≥10 fmol/mg$) | ||||
Positive | 77 | 114 | 139 $ | 270 $ |
Negative | 0 | 62 | 0 $ | 0 $ |
UK* | 0 | 36 | 0 $ | 0 $ |
Histo. Progesterone Receptor status (>10% or = 10 fmol/mg) | ||||
Positive | / | 82 | 88 $ | 216 $ |
Negative | 90 | 43 $ | 46 $ | |
UK* | 40 | 8 $ | 8 $ | |
Histo. Ki-67 status (>15%) | ||||
Positive | / | 64 | / | / |
Negative | 98 | |||
UK* | 50 | |||
No Positive Lymph Nodes (at surgery) | ||||
0 | 45 | 115 | 0 | 121 |
1 - 3 | 28 | 49 | 96 | 117 |
≥ 4 | 0 | 36 | 43 | 28 |
UK* | 4 | 12 | 0 | 4 |